Core Viewpoint - The article emphasizes the hidden dangers of HPV (Human Papillomavirus) infection, comparing it to "dark ice" on a ski slope, and highlights the importance of awareness and prevention strategies for both men and women [1][2]. Group 1: HPV Awareness and Risks - HPV infection is characterized by its prevalence and concealment, making it crucial to establish a "gender-neutral prevention" mindset [1][2]. - Most HPV infections show no early symptoms, necessitating professional screening for detection [1][2]. - Persistent high-risk HPV infections can lead to various precancerous lesions and cancers, including cervical cancer in women and penile, anal, and oropharyngeal cancers in men [1]. Group 2: Prevention Strategies - Basic protection involves maintaining a healthy sexual lifestyle and correctly using condoms to reduce transmission risk [2]. - Regular screening is essential for sexually active individuals to achieve early detection and intervention [2]. - There is a need to update perceptions about HPV, recognizing it as a concern for both genders, and to promote HPV vaccination within the appropriate age range [2]. - Knowledge dissemination is important; individuals should educate friends and family about HPV prevention to correct misconceptions and promote awareness [2].

Group 1: HPV Infection and Public Awareness - HPV infection is a significant public health issue affecting both men and women, with a notable lack of awareness regarding male HPV infection risks [2][4] - In China, cervical cancer cases reached approximately 110,000 in 2020, with around 59,000 deaths, making it the second highest burden of cervical cancer globally [2] - Misconceptions persist about male HPV infection, leading to underestimation of risks and a lack of urgency in vaccination [4][5] Group 2: HPV Vaccination Developments - The nine-valent HPV vaccine has received approval for use in males aged 16-26 in China, marking a significant step towards gender-inclusive HPV prevention [3] - Currently, there are two HPV vaccines available for males: a four-valent vaccine for ages 9-26 and a nine-valent vaccine for ages 16-26, with the latter providing broader protection [6] Group 3: Market Demand and Future Projections - The HPV vaccine market in China is projected to grow from 13.5 billion yuan in 2020 to 69 billion yuan by 2030, with the nine-valent vaccine expected to capture the largest market share [8] - Despite the potential for growth, the current vaccination rate remains low, with only about 21% of women vaccinated since the introduction of the HPV vaccine in China [9][10] - There is a significant unmet demand for HPV prevention among men, which presents a substantial market opportunity as health awareness increases [10]